Omeros (NASDAQ:OMER) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Omeros Corporation (NASDAQ:OMER) has been assigned a sell (D-) rating by Weiss Ratings, indicating negative outlook from analysts.
• The stock is currently trading at $4.39 with a 52-week low of $2.95 and a high of $13.60, reflecting significant volatility.
• Despite the negative rating, Omeros has a consensus rating of "Moderate Buy" with a target price of $18.00, as per multiple research analysts.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Several other research analysts have also commented on OMER. D. Boral Capital reiterated a "buy" rating and issued a $36.00 target price on shares of Omeros in a research report on Wednesday, September 3rd. Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a research report on Saturday, September 20th. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Friday, August 15th. Finally, HC Wainwright reiterated a "buy" rating and issued a $9.00 target price on shares of Omeros in a research report on Friday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Omeros presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Stock Down 1.1%

OMER stock opened at $4.39 on Wednesday. Omeros has a 52-week low of $2.95 and a 52-week high of $13.60. The stock's 50 day moving average is $4.20 and its two-hundred day moving average is $4.65. The company has a market capitalization of $298.78 million, a PE ratio of -2.08 and a beta of 2.32.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million for the quarter, compared to analysts' expectations of $0.31 million. As a group, sell-side analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new position in Omeros during the 1st quarter worth $579,000. Hsbc Holdings PLC acquired a new position in Omeros during the 1st quarter worth $142,000. GAMMA Investing LLC boosted its position in Omeros by 14,486.3% during the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,388 shares during the period. Sowell Financial Services LLC acquired a new position in Omeros during the 1st quarter worth $88,000. Finally, Nuveen LLC acquired a new position in Omeros during the 1st quarter worth $938,000. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.